Fusidic Acid 1% Ophthalmic Drops: Pediatric Age and Dosing
Fusidic acid 1% ophthalmic drops can be safely used in pediatric patients from birth (including neonates with gestational age >32 weeks), with a recommended dosing regimen of one drop applied twice daily for 7 days for bacterial conjunctivitis. 1, 2
Age Recommendations
The evidence strongly supports use across all pediatric age groups:
- Neonates (≥32 weeks gestational age): Fusidic acid 1% has been specifically studied and proven effective in newborns with acute conjunctivitis acquired within the first 28 days of life 2
- Infants and children (all ages): Multiple studies demonstrate safety and efficacy in children of all ages, including 206 Egyptian children with external eye infections 3
- No lower age limit specified: Unlike many ophthalmic antibiotics, fusidic acid has documented safety data from birth 2
Dosing Regimen
For Bacterial Conjunctivitis (Standard Treatment):
One drop applied twice daily for 7 days 1, 2, 4
This twice-daily dosing represents a significant practical advantage over alternatives like chloramphenicol (6 times daily) or tobramycin (4-6 times daily), particularly important for pediatric compliance.
For Bacterial Corneal Ulcer (Intensive Treatment):
The FDA label provides an intensive regimen 1:
- Days 1-2: One to two drops every 30 minutes while awake, plus awakening at 4 and 6 hours after retiring for additional drops
- Days 3-7 to 9: One to two drops hourly while awake
- Days 7-9 through completion: One to two drops four times daily
Clinical Evidence Supporting Pediatric Use
Neonatal population: A randomized trial of 456 newborns (gestational age >32 weeks) demonstrated 89% cure rate with fusidic acid versus 87.9% with chloramphenicol, with significantly better compliance (90.7% vs 78.0%, p<0.001) due to the twice-daily dosing 2
General pediatric population: In 206 Egyptian children with bacterial conjunctivitis, fusidic acid achieved 85% clinical success versus 48% with chloramphenicol (p<0.001), attributed to lower resistance rates (16% vs 55%) 3
Compliance advantage: Among children aged 2-9 years, compliance was significantly superior with fusidic acid compared to tobramycin (85% vs 47%, p<0.001), with 97% rating treatment as convenient versus 54% for tobramycin 4
Important Clinical Considerations
No age-related contraindications: Unlike fluoroquinolones which have age restrictions (e.g., most approved only for ≥1 year for conjunctivitis 5), fusidic acid has no documented lower age limit for ophthalmic use.
Formulation advantage: The carbomer vehicle provides prolonged tear film retention, allowing twice-daily dosing while maintaining therapeutic concentrations 6, 7
Safety profile: Across multiple pediatric studies, fusidic acid demonstrated excellent tolerability with minimal side effects (5% reporting mild stinging versus 14% with chloramphenicol) 6
Common pitfall to avoid: Do not confuse ophthalmic fusidic acid dosing with systemic fusidic acid dosing for other infections. The ophthalmic formulation uses a standardized 1% concentration with twice-daily dosing regardless of age or weight 1.